Acrivon Therapeutics (ACRV) Stock
Small biotech developing treatments for infections and skin conditions. Here's the price, business snapshot, and what's worth knowing about Acrivon Therapeutics in October 2026.
Acrivon Therapeutics (ACRV) is a small-cap, clinical-stage biotechnology company focused on developing therapies in the anti‑infective and dermatology area. With a market capitalisation of about $64.17 million, the company is primarily valuation-driven by clinical progress, partnerships and regulatory milestones rather than steady revenues. Investors should expect binary events — clinical readouts, regulatory interactions or licensing deals — that can materially move the share price. Typical considerations include limited cash runway at smaller market caps, potential dilution from future financings, and long development timelines intrinsic to biotech. Due diligence should focus on the company’s pipeline, trial design and timelines, management experience, and cash position. This summary is general educational information and not personalised investment advice; biotech stocks can be volatile and investors may wish to consider how such high‑risk, high‑reward exposures fit with their broader portfolio and risk tolerance.
Acrivon Therapeutics (ACRV) Stock Forecast
Analyst price target, next 12 months
$18.83
+846.4% vs today's $1.99
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Acrivon Therapeutics have a consensus 12-month target of $18.83, above the current price of $1.99.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Acrivon Therapeutics' stock with a target price of $18.83, indicating strong potential.
Financial Health
ACRIVON THERAPEUTICS is showing solid financial performance with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Trial readouts and regulatory milestones can create sharp share moves; these events are important to follow, though outcomes are uncertain.
Innovation in antimicrobials
If the pipeline shows efficacy, there is commercial potential in anti‑infective and dermatology markets; remember development is lengthy and risky.
Small‑cap dynamics
Lower market cap may mean limited liquidity and higher volatility, and the company may need additional funding, which can dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.